-
Professor Yonghong Li: Neoadjuvant Therapy for Locally Advanced Prostate Cancer—A Chinese Perspective and Clinical Balance
From January 10 to 11, 2026, the Beijing Young Urologic Oncology Physicians Academic Exchange Conference concluded successfully in Beijing. The meeting brought together leading experts and young physicians in urologic oncology to discuss cutting-edge scientific advances and clinical challenges, with the goal of fostering innovation and professional development among emerging clinicians
-
Research Breakthrough by Professor Qiang Lü’s Team at Jiangsu Provincial People’s Hospital: Imaging AI Enables Personalized Prognosis Prediction and Treatment Response Assessment in Bladder Cancer
Recently, the Department of Urology at Jiangsu Provincial People’s Hospital, led by Professor Qiang Lü, published a multicenter study in EClinicalMedicine (CAS Zone 1, Impact Factor = 10.0). By integrating multicenter MRI data, the research team developed a multimodal fusion–based deep learning model designed to achieve noninvasive preoperative survival prediction in bladder cancer patients.
-
Professor Guo Jianming: Greater Precision, Greater Intelligence—Three Frontier Technologies Driving Innovation in Urologic Oncology Care
Recently, the 15th Shanghai Urologic Oncology Academic Conference—hosted by the Shanghai Anti-Cancer Association under the theme “Precision Integration · Intelligent Leadership”—brought together leading scholars from around the world to explore advances in urologic oncology.
-
Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
Editor’s Note: Radical prostatectomy (RP) remains the primary surgical treatment for localized prostate cancer. However, a substantial proportion of patients experience biochemical recurrence (BCR) following surgery, which is closely associated…
-
Professor Xi Zheng: Apalutamide Plus ADT Enables PSA “Undetectable” Status in High-Risk Prostate Cancer Patients, Achieving a 100% 6-Month bPFS Rate
Radical prostatectomy (RP) remains the primary surgical treatment for localized prostate cancer. However, a substantial proportion of patients experience biochemical recurrence (BCR) following surgery, which is closely associated with disease progression and prostate cancer–specific mortality. Consequently, reducing postoperative BCR and improving long-term outcomes in prostate cancer patients have become major areas of clinical research focus.
-
Professor Xinan Sheng: Advancing ADC Sequencing Strategies to Overcome Drug Resistance
Beijing Urologic Oncology Young Physicians Academic Exchange Meeting Editor’s Note: From January 10 to 11, 2026, the Beijing Urologic Oncology Young Physicians Academic Exchange Meeting was successfully held in Beijing.…
-
Advancing Precision Therapy in Urothelial Carcinoma: A Collaborative Study by Professors Xuesong Li, Qi Tang, Jianhua Zhang, and Xiaoying Li Explores a Novel Approach to HER2 Assessment
A multidisciplinary team led by Professors Xuesong Li and Qi Tangfrom the Institute of Urology and Department of Urology, Peking University First Hospital, in collaboration with Professor Jianhua Zhang’s team from the Department of Nuclear Medicine and Professor Xiaoying Li’s team from the Department of Radiation Oncology, has published an original research article in Clinical…
-
Disitamab Vedotin–Based Combination Strategy Redefines First-Line Treatment for Advanced Urothelial Carcinoma, Nearly Doubling Overall Survival
In 2025, the 15th Shanghai Urologic Oncology Academic Conference was grandly held in Pudong, Shanghai. The meeting brought together leading experts in urologic oncology from China and around the world to engage in in-depth discussions on advances in the diagnosis and treatment of urothelial carcinoma, prostate cancer, renal cell carcinoma, and other major genitourinary malignancies.
Connecting Medical Expertise through Media